Prognostic associations of insulin-like growth factor-1 receptor in primary uveal melanoma

Canadian Journal of Ophthalmology

Volumn 46, Issue 6, 2011, Pages 471-476

  Al Jamal, Rana'a T ^a   Kivelä, Tero ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AVIDIN; PEROXIDASE; POLYCLONAL ANTIBODY; SOMATOMEDIN C RECEPTOR;

ARTICLE; BIOTINYLATION; CANCER MORTALITY; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CELL NUCLEUS; CELL TYPE; CHOROID MELANOMA; CILIARY BODY MELANOMA; DENSITY; DISEASE ASSOCIATION; ENUCLEATION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MACROPHAGE; MAJOR CLINICAL STUDY; MELANOMA; METASTASIS; MICROVASCULAR DENSITY; PIGMENTATION; POPULATION RESEARCH; PROGNOSIS; RELIABILITY; RETROSPECTIVE STUDY; SURVIVAL TIME;

EID: 84455203061     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.1016/j.jcjo.2011.09.013     Document Type: Article

References (25)

1. Eskelin S, Pyrhönen S, Summanen P, Hahka-Kemppinen M, Kivelä T. Tumour doubling times in metastatic malignant melanoma of the uvea: tumour progression before and after treatment. Ophthalmology. 2000;107:1443-9.
2. Singh AD, Rennie IG, Kivelä T, Seregard S, Grossniklaus H. The Zimmerman-McLean-Foster hypothesis: 25 years later. Br J Ophthalmol. 2004;88:962-7. (Pubitemid 38869565)
3. Kivelä T, Eskelin S, Kujala E. Metastatic uveal melanoma. Int Ophthalmol Clin. 2006;46:133-49. (Pubitemid 44124236)
4. Folberg R, Pe'er J, Gruman LM, et al. The morphologic characteristics of tumour blood vessels as a marker of tumour progression in primary human uveal melanoma: a matched case-control study. Hum Pathol. 1992;23:1298-305.
5. McLean IW. The biology of haematogenous metastasis in human uveal malignant melanoma. Virchows Arch A. 1993;422:433-7. (Pubitemid 23223657)
6. Foss AJE, Alexander RA, Jefferies LW, Hungerford JL, Harris AL, Lightman S. Microvessel count predicts survival in uveal melanoma. Cancer Res. 1996;56:2900-3. (Pubitemid 26199727)
7. Kujala E, Mäkitie T, Kivelä T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2003;44:4651-9. (Pubitemid 37315273)
8. Bergman L, Seregard S, Nilsson B, Lundell G, Ringborg U, Ragnarsson-Olding B. Uveal melanoma survival in Sweden from 1960 to 1998. Invest Ophthalmol Vis Sci. 2003;44:3282-7. (Pubitemid 36909760)
9. Topcu-Yilmaz P, Kiratli H, Saglam A, Söylemezoglu F, Hascelik G. Correlation of clinicopathological parameters with HGF, c-Met, EGFR, and IGF-1R expression in uveal melanoma. Melanoma Res. 2010;20:126-32.
10. Massagué J, Czech MP. The subunit structures of two distinct receptors for insulin-like growth factors I and II and their relationship to the insulin-receptor. J Biol Chem. 1982;257:5038-45. (Pubitemid 12063194)
11. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst. 2000;92:1472-89.
12. Baserga R. The insulin-like growth-factor-I receptor - a key to tumour-growth. Cancer Res. 1995;55:249-52.
13. All-Ericsson C, Girnita L, Seregard S, Bartolazzi A, Jager MJ, Larsson O. Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target. Invest Ophthalmol Vis Sci. 2002;43:1-8. (Pubitemid 34032432)
14. Economou MA, All-Ericsson C, Bykov V, et al. Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma: intercorrelation and prognostic implications. Invest Ophthalmol Vis Sci. 2005;46:4372-5. (Pubitemid 44264528)
15. Girnita A, All-Ericsson C, Economou MA, et al. The insulin-like growth factor-1 receptor inhibitor picropodophyllin causes tumour regression and attenuates mechanisms involved in invasion of uveal melanoma cells. Clin Cancer Res. 2006;12:1383-91. (Pubitemid 43342532)
16. Economou MA, Andersson S, Vasilcanu D, et al. Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma. Invest Ophthalmol Vis Sci. 2008;49:2337-42.
17. Mäkitie T, Summanen P, Tarkkanen A, Kivelä T. Microvascular loops and networks as prognostic indicators in choroidal and ciliary body melanomas. J Natl Cancer Inst. 1999;91:359-67. (Pubitemid 29102336)
18. Mäkitie T, Summanen P, Tarkkanen A, Kivelä T. Microvascular density in predicting survival of patients with choroidal and ciliary body melanoma. Invest Ophthalmol Vis Sci. 1999;40:2471-80. (Pubitemid 29455473)
19. Fuchs U, Kivelä T, Summanen P, Immonen I, Tarkkanen A. An immunohistochemical and prognostic analysis of cytokeratin expression in malignant uveal melanoma. Am J Pathol. 1992;141:169-81.
20. Kivelä T. Immunohistochemical staining followed by bleaching of melanin: a practical method for ophthalmic pathology. Br J Biomed Sci. 1995;52:325-6.
21. Bhuyan DK, Reddy PG, Bhuyan KC. Growth factor receptor gene and protein expressions in the human lens. Mech Ageing Dev. 2000;113:205-18. (Pubitemid 30068601)
22. Foss AJE, Alexander RA, Hungerford JL, Harris AL, Cree IA, Lightman S. Reassessment of the PAS patterns in uveal melanoma. Br J Ophthalmol. 1997;81:240-6. (Pubitemid 127730416)
23. + cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2001;42:1414-21.
24. Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. Springer, New York, 2000.
25. Kivelä T, Grambsch PM. Evaluation of sampling strategies for modeling survival of uveal malignant melanoma. Invest Ophthalmol Vis Sci. 2003;44:3288-93. (Pubitemid 36909761)